Effects of a Selective Cannabinoid CB2 Agonist and Antagonist on Intravenous Nicotine Self Administration and Reinstatement of Nicotine Seeking

• Islam Gamaleddin,

  Affiliations Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Canada, Addictions Program, Centre for Addiction and Mental Health, Toronto, Canada

  ⨯
• Alexander Zvonok,

  Affiliation Center for Drug Discovery, Bouve College of Health Sciences, Northeastern University, Boston, United States of America

  ⨯
• Alexandros Makriyannis,

  Affiliation Center for Drug Discovery, Bouve College of Health Sciences, Northeastern University, Boston, United States of America

  ⨯
• Steven R. Goldberg,

  Affiliation Department of Health and Human Services, Intramural Research Program, National Institute of Health, National Institute of Drug Abuse; Baltimore, Maryland, United States of America

  ⨯
• Bernard Le Foll

  * E-mail: bernard_lefoll@camh.net.

  Affiliations Translational Addiction Research Laboratory, Centre for Addiction and Mental Health, Toronto, Canada, Departments of Family and Community Medicine, Psychiatry, Pharmacology and Toxicology, Institute of Medical Science; University of Toronto, Toronto, Canada, Addictions Program, Centre for Addiction and Mental Health, Toronto, Canada

  ⨯